Radiodermatitis Market-PPT

1. Radiodermatitis Market Insights, Epidemiology, and Market Forecast By- DelveInsight Business Research

3. About Radiodermatitis Market Report It specified that in severe cases of acute radiodermatitis, premature interruption of Radio therapy might be necessary, which will eventually affect the treatment outcome and overall patient survival. Symptoms of acute radiodermatitis have been classified into three levels; grade 1 (mild erythema), grade 2 (dry desquamation), and grade 3 (severe moist desquamation). Grade 1 skin toxicity still remains a problem for around 90% of patients and grade 2 for 30% of patients.

4. With proper treatment approach Radiodermatitis can be reduced or eliminated. Combination of tropical products and oral drugs are used for effective treatment of radiodermatitis. Topical products such as Hydrophilic creams, Corticosteroids and Antibiotics are most commonly used. Oral drugs and dressing products such as Hydrogel & Hydrocolloid dressings, No sting barrier film, Honey-impregnated gauze and Silicone-coated dressings are also used as conventional options for treating radiodermatitis.

5. Apart from tropical products and oral drugs skin dressing is also treated as effective because of its antimicrobial and anti-infective properties. The silver ions used in the nylon dressing release into the skin and work quickly to relieve discomfort and improve recovery

6. The dynamics of the Radiodermatitis market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as Lutris Pharma, Otsuka Pharmaceuticals, etc. are involved in developing drugs for Radiodermatitis.

7. Kamedis ltd has topical agents in its portfolio which it develops with the science behind the Chinese medicine and its has also been developing other topical agents for symptoms which are overlapping with the symptoms of radiodermatitis, the company initiated a phase II trial for a gel named as KAM1403 in 2014, but there is no published information made available to the public regarding the further progress or results.

8. LUT014 is LutrisPharma's lead compound, being developed for the treatment of radiation-induced dermatitis in breast cancer patients. It is a novel B-Raf inhibitor which is applied topically on the skin. The technology is based on harnessing the paradoxical effect of B-Raf Inhibitors on wild type epithelial cells thus overriding MAP Kinase pathway inhibition. By reversing the inhibitory effect of EGFR inhibitors on downstream proteins in the skin cells, LUT014 is developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment.

9. Apart from this, Enveric Biosciences is developing Cannabinoid (CBD), currently in preclinical developmental stage. CBD therapy works by interacting with the body’s Endocannabinoid System, which plays an essential role in regulating skin health. Therapy is a CB1R agonists, and inhibits the activation of mastocytes and the release of histamine. Source- Radiodermatitis Market Research Report

10. Thank You